N30 Pharma, a Boulder, Colorado-based biopharmaceutical company focused on developing s-nitrosothiol (SNO)-based therapies for major unmet needs in respiratory, cardiovascular, and inflammatory diseases, has completed a $10m financing.
In conjuction with the funding, Dr. Howard Furst of Deerfield Management, joins the company’s board of directors.
The financing will provide resources to move N30 Pharma’s first drug, N6022, into human testing, as well as support the development of other novel new drugs from its discovery and development platform.
N30 drugs target s-nitrosoglutathione reductase (GSNOR), a druggable enzyme that consumes s-nitrosoglutathione (GSNO), a central regulator of the endogenous nitric oxide pool.
GSNO, and other SNO’s are important modulators of inflammation as well as airway and vascular smooth muscle.
GSNO, and other SNO’s are important modulators of inflammation as well as airway and vascular smooth muscle.
FinSMEs
11/05/2010